IFP Advisors’s Carisma Therapeutics CARM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-206
Closed -$9 5040
2025
Q4
$9 Hold
206
﹤0.01% 4842
2025
Q3
$56 Hold
206
﹤0.01% 4645
2025
Q2
$81 Hold
206
﹤0.01% 4747
2025
Q1
$63 Hold
206
﹤0.01% 3975
2024
Q4
$86 Hold
206
﹤0.01% 4082
2024
Q3
$203 Hold
206
﹤0.01% 3207
2024
Q2
$313 Hold
206
﹤0.01% 3118
2024
Q1
$467 Hold
206
﹤0.01% 2987
2023
Q4
$603 Hold
206
﹤0.01% 2860
2023
Q3
$871 Hold
206
﹤0.01% 3026
2023
Q2
$1.81K Sell
206
-4,140
-95% -$22.5K ﹤0.01% 2912
2023
Q1
$11.2K Buy
4,346
+4,135
+1,960% +$39.4K ﹤0.01% 2242
2022
Q4
$11K Hold
211
﹤0.01% 3310
2022
Q3
$11K Hold
211
﹤0.01% 3554
2022
Q2
$11K Hold
211
﹤0.01% 3305
2022
Q1
$11K Hold
211
﹤0.01% 3305
2021
Q4
$4K Hold
211
﹤0.01% 2557
2021
Q3
$4K Hold
211
﹤0.01% 2621
2021
Q2
$19K Buy
+211
New +$13.5K ﹤0.01% 1950
2018
Q2
Sell
-100
Closed -$2K 3885
2018
Q1
$2K Hold
100
﹤0.01% 3481
2017
Q4
$2K Hold
100
﹤0.01% 3532
2017
Q3
$3K Hold
100
﹤0.01% 3591
2017
Q2
$3K Hold
100
﹤0.01% 3587
2017
Q1
$4K Buy
100
+50
+100% +$2.08K ﹤0.01% 3391
2016
Q4
$2K Buy
+50
New +$2.2K ﹤0.01% 3620

Other funds holding CARM

IFP Advisors's CARM Position: Q1 2026 in Review

IFP Advisors sold out of Carisma Therapeutics (CARM) in Q1 2026, closing a stake of 206 shares — an estimated $9 sold.

IFP Advisors first reported a position in CARM in Q4 2016 and held it in 25 quarters. The position peaked at $19K in Q2 2021. 3 funds tracked by Wall St. Rank hold CARM as of Q1 2026.

  • IFP Advisors reported no remaining Carisma Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IFP Advisors sold 206 Carisma Therapeutics shares in Q1 2026, an estimated $9.
  • IFP Advisors first reported a position in Carisma Therapeutics in Q4 2016 and held it in 25 quarters.
  • IFP Advisors's Carisma Therapeutics position peaked at $19K in Q2 2021.
  • 3 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.